Cure8 news brief
Cure8 news brief
Researchers have found a short peptide in potato protein with antioxidant and anti-inflammatory properties and are testing it as a possible oral treatment for intestinal inflammation — a potential new, plant-derived option for people with IBD if preclinical and clinical testing succeed.
Adult patients with IBD (ulcerative colitis or Crohn’s), patients seeking non-biologic oral therapies, gastroenterology clinicians, and researchers in drug discovery or microbiome/immune-pathway fields.
Northeastern University researchers have identified a short, six–amino-acid peptide sequence found in potato protein that shows anti-inflammatory and antioxidant activity in lab studies. The team is synthesizing the peptide in the lab, studying how it enters cells and which proteins it binds to, and exploring whether it can promote helpful gut bacteria.
Next steps described by the researchers include testing the compound orally in mouse models of colitis and, if those results are promising, proceeding to clinical trials. The researchers envision developing the peptide into a concentrated supplement or oral therapy that targets inflammation without broadly suppressing the immune system.
The article reports early-stage laboratory research and plans for mouse studies; it does not present human clinical trial data. Outcomes from preclinical studies are preliminary and require clinical testing to determine real-world safety and effectiveness.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.